Literature DB >> 31264684

Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.

Li-Hui Tseng1,2, Federico De Marchi1, Aparna Pallavajjalla1, Erika Rodriguez1, Rena Xian1, Deborah Belchis1, Christopher D Gocke1,3, James R Eshleman1,3, Peter Illei1, Ming-Tseh Lin1.   

Abstract

OBJECTIVES: To propose an operating procedure for validation of discordant trunk driver mutations.
METHODS: Concordance of trunk drivers was examined by next-generation sequencing in 15 patients with two to three metastatic lung cancers and 32 paired primary and metastatic lung cancers.
RESULTS: Tissue identity was confirmed by genotyping 17 single-nucleotide polymorphisms within the panel. All except three pairs showed concordant trunk drivers. Quality assessment conducted in three primary and metastatic pairs with discordant trunk drivers indicates metastasis from a synchronous or remote lung primary in two patients. Review of literature revealed high discordant rates of EGFR and KRAS mutations, especially when Sanger sequencing was applied to examine primary and lymph node metastatic tumors.
CONCLUSIONS: Trunk driver mutations are highly concordant in primary and metastatic tumors. Discordance of trunk drivers, once confirmed, may suggest a second primary cancer. Guidelines are recommended to establish standard operating procedures for validation of discordant trunk drivers. © American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 EGFRzzm321990 ; zzm321990 KRASzzm321990 ; Discordance; Lung cancers; Quality assessment; Trunk driver mutations

Mesh:

Substances:

Year:  2019        PMID: 31264684      PMCID: PMC6779251          DOI: 10.1093/ajcp/aqz077

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  47 in total

1.  Inter-laboratory evaluation of SNP-based forensic identification by massively parallel sequencing using the Ion PGM™.

Authors:  M Eduardoff; C Santos; M de la Puente; T E Gross; M Fondevila; C Strobl; B Sobrino; D Ballard; P M Schneider; Á Carracedo; M V Lareu; W Parson; C Phillips
Journal:  Forensic Sci Int Genet       Date:  2015-04-15       Impact factor: 4.882

2.  Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

Authors:  Yasushi Yatabe; Keitaro Matsuo; Tetsuya Mitsudomi
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

3.  Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.

Authors:  Winfried H Alsdorf; Till S Clauditz; Tobias Hoenig; Alexander Quaas; Hüseyin Sirma; Alexandra M Koenig; Jakob Izbicki; Guido Sauter; Andreas H Marx; Tobias J Grob
Journal:  Exp Mol Pathol       Date:  2012-09-27       Impact factor: 3.362

4.  Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers.

Authors:  Yih-Leong Chang; Chen-Tu Wu; Jin-Yuan Shih; Yung-Chie Lee
Journal:  Ann Surg Oncol       Date:  2010-09-02       Impact factor: 5.344

5.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

Authors:  Zhi-Yong Chen; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Xue-Ning Yang; Zhi-Hong Chen; Jin-Ji Yang; Qing Zhou; Hong-Hong Yan; She-Juan An; Hua-Jun Chen; Ben-Yuan Jiang; Tony S Mok; Yi-Long Wu
Journal:  Oncologist       Date:  2012-06-06

6.  Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

Authors:  Sarah Park; Alison J Holmes-Tisch; Eun Yoon Cho; Young Mog Shim; Jinkook Kim; Hyo Song Kim; Jeeyun Lee; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Pasi A Jänne; Myung-Ju Ahn
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

7.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Authors:  Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

8.  Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status.

Authors:  Gayane Badalian; Tamás Barbai; Erzsébet Rásó; Katalin Derecskei; Miklós Szendrôi; József Tímár
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

9.  Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.

Authors:  Leina Sun; Qiang Zhang; Huanling Luan; Zhongli Zhan; Changli Wang; Baocun Sun
Journal:  J Exp Clin Cancer Res       Date:  2011-03-17

Review 10.  Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective.

Authors:  Guoli Chen; Zhaohai Yang; James R Eshleman; George J Netto; Ming-Tseh Lin
Journal:  Biomed Res Int       Date:  2016-09-06       Impact factor: 3.411

View more
  1 in total

1.  IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.

Authors:  Erika F Rodriguez; Federico De Marchi; Parvez M Lokhandwala; Deborah Belchis; Rena Xian; Christopher D Gocke; James R Eshleman; Peter Illei; Ming-Tseh Li
Journal:  Cancer Med       Date:  2020-04-25       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.